Neoadjuvant therapy in gall bladder cancer improves resectability and survival: a prospective study

Puntos clave

• Enhanced resectability correlates with improved survival in gall bladder cancer patients, showcasing the therapeutic benefit.
• Survival rates improved markedly with neoadjuvant therapy; 70% of patients achieved complete resection after treatment.
• Prospective study design allows real-time assessment of treatment efficacy on gall bladder cancer outcomes.
• Potential for developing standardized treatment guidelines exists, emphasizing the need for larger-scale trials.